Hims & Hers Health is trading at €25.62, down -4.04%, after reporting a wider-than-expected Q2 GAAP loss of $0.37 per share versus a $0.05 estimate.
- Revenue reached $753.2 million, beating expectations, but branded weight-loss drug costs pressured profitability.
- Gross margins fell as the company transitioned from compounded to branded GLP-1 medications.
- Decline extends investor concern following August 10 earnings release despite raised full-year revenue guidance; trading activity remains elevated as markets reassess near-term profitability and cash flow.